Menu ×


Hormone Replacement Therapy Market Analysis by Replacement Therapy (Estrogen, Human Growth Hormone, Thyroid, and Testosterone Replacement Therapy); by Administration Route (Parenteral, Transdermal, and Oral); and by Indication (Cancer, Growth Hormone Deficiency, Menopause, Male Hypothyroidism, Hypothyroidism, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Report ID: 866
  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • Orion Pharma AB to acquire the clearance for darolutamide indication in the combination with docetaxel from U.S. Food and Drug Administration (FDA). The product is developed for the treatment of metastatic hormone-sensitive prostate cancer shortly known as (mHSPC).

  • Genentech, Inc. to release positive results from the Phase III SKYSCRAPER-01 study. The study was being conducted to monitor the anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) vs Tecentriq alone as an initial (first-line) to find the cure for people living with advanced or metastatic non-small cell lung cancer (NSCLC).

Global Hormone Replacement Therapy Market Size, Forecast, and Trend Highlights Over 2023 - 2033

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 32 Billion

Forecast Year Market Size (2033)

~ USD 57 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)


The global hormone replacement therapy market is estimated to garner a revenue of ~USD 57 billion by the end of 2033 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 32 billion in the year 2022. The growth of the market is primarily attributed to the higher prevalence of chronic conditions such as hypogonadism in adult males across the globe. For instance, globally, hypogonadal males account for approximately 42% of men over the age of 45 and 55% of men in their 80s. Moreover, rising awareness regarding the post- menopausal issues among women is another major factor which is driving the growth of the market over the projected forecast period.

hormone replacement therapy market overview market imageGet more information on this report:Request Sample PDF

Global hormone replacement therapy market trends such as, skyrocketing investment by the government in the R&D of new medical technology and the growing prevalence of high blood pressure & hypertension are projected to influence the growth of the market positively over the forecast period. For instance, it is estimated that in every 4 adults, 1 of them aged between 20 to 45 suffers from high blood pressure worldwide. Additionally, in 2018, around 45% of the global population was projected to live with hypertension. Hence, all these factors are anticipated to propel the growth of the market over the forecast period.

Global Hormone Replacement Therapy Market: Growth Drivers and Challenges

Growth Drivers

  • Higher Number of Women Hitting Menopause - As of 2020, in the USA, around 50% of women aged 35 or above were facing sleep problems, 45% of them had skin dryness, 30% suffering from depression, and 30% women were living with night sweats due to menopause. Menopause is a time that comes in a women’s life after she has her last menstrual cycle. Menopause is commonly diagnosed after 12 months without having a menstrual period which generally occurs in the 40s or 50s. During this period, women face severe hormonal changes that can affect their daily life. Hence, hormone replacement therapy becomes beneficial to soothe the symptoms of menopause.

  • Growing Cases of Anxiety Disorders - In 2019, around 4% of the global population was estimated to be suffering from anxiety disorders.

  • Spiking Prevalence of Thyroid in Modern Population - For instance, approximately 10 out of 100,000 women and 3 out of 100,000 men are projected to be living with thyroid.

  • Worldwide Proliferation in Hypertension - For instance, approximately 1.50 billion people globally between the ages of 30-79 had hypertension in 2021.

  • Utilization of Hormone Replacement Therapy to Cure Liver Disease - It has been observed that around 1.8 million people die due to liver disease every year across the globe.


  • Possibilities of Side-Effects of the Therapy – Hormone replacement therapy is anticipated to cause some problems with digestive system of that person who takes this therapy. A person feels sick, have diarrhea, constipation, and even loss of appetite.

  • Requirement for Higher Initial Investment

  • Lack of Skilled Medical Professionals

The global hormone replacement therapy market is segmented and analyzed for demand and supply by administration route into parenteral, transdermal, and oral, out of which, the transdermal segment is projected to witness noteworthy growth over the forecast period. The growth of the segment is accounted to the rising demand for transdermal drug delivery and ease of application. For instance, it is estimated that over 1 million transdermal patches are produced worldwide every year.

Global Hormone Replacement Therapy Market Regional Synopsis

The North America hormone replacement therapy market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market is ascribed to the significant growth in the geriatric population along with the significant presence of a well-structured healthcare infrastructure. World Bank released a set of data showing the geriatric population in the United States reached 56,545,938 in 2021. Moreover, rising cases of cancer and spiking penetration of major key players of the market in the region are further expected to hike the growth of the market over the forecast period.

Market Segmentation

Our in-depth analysis of the global hormone replacement therapy market includes the following segments:

     By Replacement Therapy

  • Estrogen
  • Human Growth Hormone
  • Thyroid
  • Testosterone Replacement Therapy

     By Administration Route

  • Parenteral
  • Transdermal
  • Oral

     By Indication

  • Cancer
  • Growth Hormone Deficiency
  • Menopause
  • Male Hypothyroidism
  • Hypothyroidism
  • Others

Top Featured Companies Dominating the Global Hormone Replacement Therapy Market

  • AbbVie Inc.

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Abbott Laboratories
  • Novo Nordisk A/S
  • Genentech, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Mylan N.V.
  • Bayer AG
  • Eli Lilly and Company


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved